Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Robert J MotzerBernard EscudierSaby GeorgeHans J HammersSandhya SrinivasScott S TykodiJeffrey A SosmanElizabeth R PlimackGiuseppe ProcopioDavid F McDermottDaniel CastellanoToni K ChoueiriFrede DonskovHoward GurneyStéphane OudardMartin RichardetKatriina PeltolaAjjai S AlvaMichael CarducciJohn WagstaffChristine ChevreauSatoshi FukasawaYoshihiko TomitaThomas C GaulerChristian K KollmannsbergerFabio A SchutzJames LarkinDavid CellaM Brent McHenryShruti Shally SaggiNizar M TannirPublished in: Cancer (2020)
CheckMate 025 compared the effects of nivolumab (a novel immunotherapy) with those of everolimus (an older standard-of-care therapy) for the treatment of advanced kidney cancer in patients who had progressed on antiangiogenic therapy. After 5 years of study, nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment, and improving quality of life with a manageable safety profile. The results demonstrate that the clinical benefits of nivolumab versus everolimus in previously treated patients with advanced kidney cancer continue in the long term.
Keyphrases
- open label
- phase iii
- phase ii
- clinical trial
- newly diagnosed
- healthcare
- study protocol
- ejection fraction
- end stage renal disease
- palliative care
- double blind
- squamous cell
- squamous cell carcinoma
- physical activity
- randomized controlled trial
- young adults
- radiation therapy
- stem cells
- combination therapy
- patient reported outcomes
- bone marrow
- pain management
- rectal cancer
- health insurance